Saltar al contenido
Merck

Mutations of the Igbeta gene cause agammaglobulinemia in man.

The Journal of experimental medicine (2007-08-22)
Simona Ferrari, Vassilios Lougaris, Stefano Caraffi, Roberta Zuntini, Jianying Yang, Annarosa Soresina, Antonella Meini, Giantonio Cazzola, Cesare Rossi, Michael Reth, Alessandro Plebani
RESUMEN

Agammaglobulinemia is a rare primary immunodeficiency characterized by an early block of B cell development in the bone marrow, resulting in the absence of peripheral B cells and low/absent immunoglobulin serum levels. So far, mutations in Btk, mu heavy chain, surrogate light chain, Igalpha, and B cell linker have been found in 85-90% of patients with agammaglobulinemia. We report on the first patient with agammaglobulinemia caused by a homozygous nonsense mutation in Igbeta, which is a transmembrane protein that associates with Igalpha as part of the preBCR complex. Transfection experiments using Drosophila melanogaster S2 Schneider cells showed that the mutant Igbeta is no longer able to associate with Igalpha, and that assembly of the BCR complex on the cell surface is abrogated. The essential role of Igbeta for human B cell development was further demonstrated by immunofluorescence analysis of the patient's bone marrow, which showed a complete block of B cell development at the pro-B to preB transition. These results indicate that mutations in Igbeta can cause agammaglobulinemia in man.